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Abstract: Melatonin is an indolic hormone that regulates a plethora of functions ranging from the
regulation of circadian rhythms and antioxidant properties to the induction and maintenance of
tumor suppressor pathways. It binds to specific receptors as well as to some cytosolic proteins,
leading to several cellular signaling cascades. Recently, the involvement of melatonin in cancer
insurgence and progression has clearly been demonstrated. In this review, we will first describe
the structure and functions of melatonin and its receptors, and then discuss both molecular and
epidemiological evidence on melatonin anticancer effects. Finally, we will shed light on potential
cross-talk between melatonin signaling and the Hippo signaling pathway, along with the possible
implications for cancer therapy.
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1. Introduction
Melatonin (N-acetyl-5-methoxy tryptamine) is a pleiotropic neurohormone mainly secreted by
the pineal gland and partially by other peripheral organs that are widely distributed, including in the
gut, gonads, retina, and immune-competent cells [1]. Its production is tightly regulated by light/dark
signals coming from the retina, following a circadian rhythm, with a peak during the night and
relatively lower concentrations during the day, when the light turns off its production [2–4]. Melatonin
peak levels are higher in new-borns and start to decline in the elderly [5].
The physiological input for pineal melatonin production starts in a subgroup of Retinal Ganglion
Cells sensitive to a specific light-blue wavelength [2,3] that transmits information to the pineal
gland through the retino-hypotalamic tract and induces the transcription and stabilization of
N-acetyltransferase (NAT) enzyme [6,7]. This latter, together with the hydroxyindole-O-methyltransferase
enzyme (HIOMT), is responsible for converting serotonin to melatonin [3,8,9]. During the day, light
inhibits NAT and melatonin production [10].
Once produced, melatonin is released into the cerebrospinal fluid and capillaries and reaches
all the body’s tissues, with concentrations between picomolars and nanomolars. It is metabolized
by the liver and secreted in the urine, where its major metabolite, 6-sulfatoxy-melatonin (aMT6s),
correlates with melatonin’s nocturnal plasma peaks [11–13]. Chronic exposure to artificial light at
night deregulates melatonin levels, as shown in rodent models and in cohort studies of night-shift
workers [14]. In addition, an inverse correlation between melatonin levels and tumor incidence has
been reported in prospective nested case control studies [15–22], suggesting that supplementation with
melatonin might be proposed as cancer chemopreventive treatment in human clinical studies [23–25].
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2. Melatonin Membrane Receptors
Melatonin controls a plethora of physiological processes including regulation of sleep-wake
rhythm, temperature and physiologic activities in the circadian clock, blood pressure regulation,
stimulation of bone metabolism, immune function, reproductive functions, memory formation, cell
differentiation and proliferation, inhibition of oxidative stress and inflammation processes [26–36].
All these functions employ both receptor-dependent and receptor-independent mechanisms. The two
main membrane receptors, MTNR1A and MTRN1B, also known as MT1 and MT2, belong to the
superfamily of G-protein coupled receptors (GPCRs), which constitute the largest family of membrane
receptors with approximately 1000 members and respond to a wide variety of extracellular stimuli
(hormones, neurotransmitters, or growth factors) controlling physiological processes such as cellular
metabolism, secretion, cell differentiation, and growth [37]. MT1 and MT2 exist in both homo-dimeric
and hetero-dimeric forms, and share high sequence homology [38]. They are expressed in several
areas of the central nervous system (CNS), in the retina, the gastro-intestinal tract, arteries and
immune cells [33]. They show different affinities for melatonin: MT2 has a 5-fold higher affinity than
MT1, in both humans and other species [38–40]. MT3, a low affinity binding receptor, is a Quinone
reductase 2, an enzyme that catalyzes the reduction of quinones into quinols having important
implications on oxidative stress [41,42].
MT1 and MT2 Mediated Signal Transduction
Upon agonist binding, cytoplasmic heterotrimeric G proteins that are comprised of Gα, β and
γ subunits dissociate from GPCR transmembrane receptors [43]. The 15 different Gα subunits are
classified into four families, Gα12/13, Gαq/11, Gαi/o, and Gαs [44], which in turn act on individual
effectors such as adenylate cyclase (AC), phosphodiesterase (PDE), phospholipase C (PLC), or ion
channels to affect the levels of associated second messengers including 3′,5′-cyclic adenosine or
guanosine monophosphate (cAMP and cGMP), inositol triphosphate (IP3), and calcium [45].
MT1 and MT2 receptors mainly associate with Gαi proteins and to a lesser extent with Gαq/11
and Gαs proteins [46–55] which can couple to multiple signal transduction cascades, either alternately,
or concomitantly in the same tissue [56]. In general, the signal transduction pathways induced by
melatonin receptors are cell type and tissue specific [33] leading to unique cellular responses and
suggesting a potential crosstalk with other signaling pathways. For example, MT1 receptor activation
by melatonin may lead to different and in some cases opposite signaling pathways, depending on
which Gα protein is activated. In general, Gαi activation leads to the inhibition of the adenyl cyclase
activity with consequent inhibition of cyclic AMP (cAMP) formation, inhibition of protein kinase A
(PKA) activity, and reduced phosphorylation and transcriptional activity of the cAMP-responsive
element binding (CREB) as well as activation of phospholipase C β [48,57–64]. Conversely, in other
systems such as Cos7 fibroblasts, HEK293 and MCF7 cells, activation of Gαq and Gαs proteins coupled
to MT1 receptors leads to an increase of cAMP formation. Increased intracellular cAMP in turn activates
PKA and PKC, which causes the inhibition of NF-κB (Nuclear Factor Kappa-light-chain-enhancer
of activated B cells) with consequent derepression of the oncosuppressor p27kip1 and attenuation
of the androgen response in prostate cells [53–55,65–67], activation of JNK in Cos7 cells [68], and
phosphorylation of ERK1/2 in HEK 293 cells [69].
3. Melatonin and Nuclear Receptors: Contrasting Evidence
In the 90’s and a few years later, some studies showed that melatonin and its analogues can
bind in vitro to nuclear receptors belonging to the family of retinoid Z receptor/Retinoid Orphan
Receptor alpha (RZR/RORα) [70–74]. These receptors are organized into the following structural
domains: a N-terminal transactivating domain, a DNA-binding domain, a variable domain, and
a ligand-binding domain [75]. Once activated, they bind ROR response elements (ROREs) on
the chromatin (TAAA/TNTAGGTCA motif) primarily as monomers [76–79] and regulate genes
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involved in cell differentiation, immune response, lipid metabolism, CNS development, tumour
growth and inflammation [33,71–73,80–86]. Biologically, a role for melatonin in the downregulation
of 5-lipooxygenase gene through RZR/RORα receptors has been shown by Carlsberg’s group in
B lymphocytes [87]. However, Carlberg’s group in 1997 retracted the report that melatonin is a direct
ligand of these nuclear receptors because they could not reproduce their results. Yet, the above
mentioned study suggested a positive regulation of RZR/RORα by melatonin either in transcriptional
activation or in repression of target genes [70–73,87], even if a direct binding of melatonin to receptors
is arguable. In 2011, the group of Lardone and coworkers showed a direct interaction between
melatonin and nuclear receptors in T lymphocytes and a negative regulation of nuclear RORα levels
by melatonin. Other works showed a possible negative regulation of RZR/RORα by melatonin in
different experimental systems [88,89], while in models of gastric cancer melatonin has been shown to
negatively regulate RZR/RORγ [90].
4. Oncoprotective Role of Melatonin: In Vitro Evidence
Epidemiological studies have suggested that melatonin decreases the risk of developing different
types of cancer. Recently, the molecular mechanism by which melatonin exerts its anticancer effects
has been revised [91,92]. This might occur either through downregulation of oncogenic pathways or
via activation of tumor suppressor activities.
Melatonin can activate phosphorylation cascades, mediated by MEK1/2, ERK1/2, JNK and p38
MAPK, through binding to its membrane receptors MT1 and MT2 [93–97]. In particular, our group
and others have shown that the binding of melatonin to MT1 and MT2 triggers a phosphorylation
cascade, mediated in part by p38, which leads to the activation of p53 through phosphorylation of
Ser15. This leads to a transient cell cycle arrest through the accumulation of tumor suppressive proteins
(see Figure 1) and the induction of DNA repair mechanisms that prevent the accumulation of DNA
mutations in response to DNA damage induced by chemotherapeutic agents or ionizing radiations.
These events occurred both in normal and tumor cells only in the presence of intact MT1 and MT2
signaling [98–100].
Melatonin also causes the reduction of the abundance and the transcriptional activity of the
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor, leading to
reduced proliferation and metastasis as well as increased apoptosis in basal conditions or in response
to chemotherapeutic agents in several models of cancer including breast cancer, prostate cancer, colon
and gastric cancer, pancreatic cancer, renal carcinoma, and hepatoma [55,93,95,101–104]. Part of the
inhibition of the NF-κB transcriptional activity is elicited through the activation of JNK and p38 [93].
Oncosuppressive pathways induced by melatonin were also observed in vitro in glioblastoma [105,106]
and osteosarcoma [107]. It is important to mention that beside its effects on cancer cells, melatonin
protects from apoptosis normal cells like spermatozoa [108], cells in the liver [109], in the nervous [110]
and immune systems [84,111–120], in which melatonin counteracts aging-related diseases, and
stimulates immune cells activation and proliferation, respectively. Melatonin increases the number
of effector T cells and decreases the number of regulative T cells (Tregs) [119,120]. Tregs have an
inhibitory effect on anti-cancer immunity and some tumor cells are able to upregulate and recruit Tregs
to escape the antitumor effect of the cellular immune system [121].
In summary, melatonin promotes apoptosis in certain circumstances, for example in cancer cells
and in Treg cells, while it protects normal cells from apoptosis, including cells of the immune system
that actively counteract infections and tumors.
The net effect of these opposite mechanisms is the protection of the whole organism from
inflammation, aging-related diseases, cancer development, and progression.
Melatonin also inhibits cancer cell migration and invasiveness by increasing the expression of cell
adhesion molecules [122–125] and by reducing the expression of the RhoA kinase ROCK involved in
progression and metastasization of several tumors [124,126,127].
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Moreover, melatonin has been shown to inhibit the expression of stemness-related
genes, [105,128,129] to inhibit stemness-related pathways [105,106] to improve the response to several
anticancer therapies [102,103,130–134], and to inhibit angiogenesis [127,135–146]. Finally, in Androgen
Receptor (AR) and Estrogen Receptor (ER) positive cells, melatonin inhibits the AR [54,65,147–149]
and ER response [128,150–153] through different mechanisms either mediated by MT1 or independent
of MT1 receptor binding.
In general, MT1 seems to play a prominent role in triggering anti-tumor cellular responses
mediated by melatonin [53–55,154–159], although in some experimental models MT2 has been shown
to be required too [160,161].
Melatonin can also counteract tumor formation through mechanisms independent of MT1 and
MT2. For example, through calmodulin (CaM) binding, melatonin interferes with the transcription
of Estrogen Receptor α (ERα) genes in response to estrogen (E2). The formation of a melatonin–CaM
complex, in fact, impairs the formation of a proper E2–ERα–CaM complex on ERα targets [153].
Moreover, in models of colon cancer, gastric cancer [82,90,162,163], and ovarian carcinoma [164],
nuclear RZR/ROR receptors were proposed to contribute to the tumor-suppressive effects of melatonin
even if, as mentioned above, a direct interaction between melatonin and RZR/RORα receptors is still a
matter of debate because no one has yet reproduced Carlberg et al.’s pioneering results that show a
direct interaction between melatonin and nuclear receptors (Figure 1).
Int. J. Mol. Sci. 2017, 18, 1913  4 of 25 
 
Moreover, melatonin has been shown to inhibit the expression of stemness-related genes, 
[105,128,129] to inhibit stemness-related pathways [105,106] to improve the response to several 
anticancer therapies [102,103,130–134], and to inhibit angioge esis [127,135–146]. Finally  in 
Androgen Receptor (AR) and Estrogen Receptor (ER) positive cells, melatonin inhibits the AR 
[54,65,147–149] and ER response [128,150–153] through different mechanisms either mediated by 
MT1 or independent of MT1 receptor binding. 
In general, MT1 seems to play a prominent role in triggering anti-tumor cellular responses 
mediated by melatonin [53–55,154–159], although in some experimental models MT2 has been 
shown to be required too [160,161]. 
Melatonin can also counteract tumor formation through mechanisms independent of MT1 and 
MT2. For example, through calmodulin ( a ) binding, melatonin interferes with the transcription 
of Estrogen Receptor α (ERα) genes in res  t  estrogen (E2). The formation of a melatonin–CaM 
complex, in fact, impairs the formatio    roper E2–ERα–CaM complex on ERα targe s [153]. 
Moreover, in models of colon cancer, gastric cancer [82,90,162,163], and ovarian carcinoma [164], 
nuclear RZR/ROR receptors were proposed to contribute to the tumor-suppressive effects of 
melatonin even if, as mentioned above, a direct interaction between melatonin and RZR/RORα 
receptors is still a matter of debate because no one has yet reproduced Carlberg et al.’s pioneering 
results that show a direct interaction between melatonin and nuclear receptors (Figure 1). 
 
Figure 1. Oncosuppressive mechanisms mediated by melatonin. Melatonin (MLT) signaling has been 
shown to reduce the abundance and transcriptional activity of the NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) transcription factor as well as to activate 
phosphorylation cascades mediated by mitogen-activated protein kinases (MAPKs) such as MEK1/2, 
ERK1/2, JNK, and p38. Both NF-κB inhibition and MAPKs activation in turn inhibit cell growth and 
motility, and promote apoptosis and DNA damage repair through mechanisms involving the 
accumulation of oncosuppressors such as p53, p27kip1, and p21, activation of DNA repair complexes 
such as P53/PML/H2AX on DNA damage sites, and transcriptional control of genes involved in the 
cell cycle, apoptosis, and invasiveness. Even though it is still a matter of debate, there is the 
possibility that melatonin can also bind to nuclear receptors RZR/ROR, controlling the transcription 
of RORE (ROR response Elements) on genes of the retinoic acid response, among which are several 
genes controlling cell cycle progression and cell growth (p21, 5-lipoxygenase, and others). Finally, 
melatonin can bind to the intracellular protein calmodulin (CaM) and reduce the Estrogen Receptor 
α (ERα) response in ER positive cells by impairing the formation of a proper E2–ERα–CaM complex 
on Estrogen Receptor Elements (EREs) on target genes. Arrows indicate activation, while dashed and 
blunt lines indicate inhibition. Activation indicates an increase in protein or activity levels, while 
inhibition indicates a decrease in protein or activity levels. 
Figure 1. Oncosuppressive mechanis s mediated by melatonin. elatonin (MLT) signaling
has been shown to reduce the abundance and transcriptional activity of the NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells) transcription factor as well as to activate
phosphorylation cascades mediated by mitogen-activated protein kinases (MAPKs) such as MEK1/2,
ERK1/2, JNK, and p38. Both NF-κB inhibition and MAPKs activation in turn inhibit cell growth
and motility, and promote apoptosis and DNA damage repair through mechanisms involving the
accumulation of oncosuppressors such as p53, p27kip1, and p21, activation of DNA repair complexes
such as P53/PML/H2AX on DNA damage sites, and transcriptional control of genes involved in
the cell cycle, apoptosis, and invasiveness. Even though it is still a matter of deb te, there is the
possibility that melatonin can also bind to nuclear receptors RZR/ROR, controlling the transcription
of RORE (ROR response Elements) on genes of the retinoic acid response, among which are several
genes controlling cell cycle progression and cell growth (p21, 5-lipoxygenase, and others). Finally,
melatonin can bind to the intracellular protein calmodulin (CaM) and reduce the Estrogen Receptor
α (ERα) response in ER positive cells by impairing the formation of a proper E2–ERα–CaM complex
on Estrogen Receptor Elements (EREs) on target genes. Arrows indicate activation, while dashed and
blunt lines indicate inhibition. Activation indicates an increase in protein or activity levels, while
inhibition indicates a decrease in protein or activity levels.
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5. Melatonin Antioxidant Properties
Melatonin is an antioxidant, anti-inflammatory and anti-angiogenic molecule. Various oxidative
reactions normally occurring in the organism, mainly in mitochondria, generate free radicals from
reactive oxygen species (ROS) and reactive nitrogen species (RNS). In normal cells, these species are
required for signal transduction before their elimination through endogenous antioxidant compounds
and enzymes. The aberrant accumulation of reactive oxidant species can cause multiple lesions in
macromolecules (nucleic acids, proteins, and lipids), leading to their damage. In cancer the aberrant
activation of pathways leading to cell proliferation and invasiveness causes a hyperaccumulation of
ROS and RNS. Endogenous antioxidants are not sufficient to counteract this accumulation. However,
cancer cells often acquire resistance to oxidative stress and escape free radical damage. In that context,
ROS accumulation in turn promotes tumor development and progression and induces increased
cell proliferation, evasion of apoptosis, tissue invasion-metastasis, and angiogenesis (reviewed
in [165,166]).
Melatonin counteracts the oxidative stress through multiple mechanisms [167]. It stimulates the
expression and activity of antioxidative enzymes [168]. It inhibits the expression of QR2 enzyme at
pharmacological concentrations that are higher than those required for MT1 and MT2 activation. Given
that QR2 reduces quinones into quinols, and thereby functions as an indirect producer of ROS, it has
been proposed that the inhibition of QR2 activity may in part explain the antioxidant properties of
melatonin [42].
Moreover, melatonin preserves the integrity and the function of the mitochondria [169–171].
Through these mechanisms, melatonin prevents the genotoxic and carcinogenic effects of oxidative
stress and helps to maintain cell function and survival.
6. Clinical Studies
Melatonin is involved in several physiological processes, and its deficiency (or an altered
expression of its receptors) has been associated with a number of chronic diseases including several
types of cancer [172–176]. Conversely, a number of randomized and controlled clinical trials
showed that exogenously administered melatonin has, among several biological effects, anti-cancer,
anti-inflammatory and antioxidant properties in different cancer types, thus improving the responses
of patients to traditional therapies and reducing the side effects of the latter [23–25].
In the following section, we will present results from observational, translational and cohort
prospective studies on the association between pre-diagnostic prolonged exposure to daylight and low
melatonin serum levels and subsequent cancer development.
6.1. Circadian Disruption and Increased Light Exposure Contribute to Increased Cancer Risk
In 1991 [177], Hann and co-workers showed a reduced risk of breast cancer in blind women.
Based on the observation that blind women are constantly in the dark and that melatonin production
is increased during the night [178], this study suggested for the first time a possible protective role of
melatonin in blind women against the risk of developing cancer. Later observations supported this
hypothesis [179–181]. Conversely, several bodies of evidence showed that disruption of the circadian
rhythm, in part as a consequence of night-shift work and light pollution at night (LAN), increases the
risk of developing breast cancer [182–184] and prostate cancer [185]. Importantly, our group and others
showed an inverse correlation between night work, circadian disruption and melatonin production
suggesting a protective role of melatonin against diseases associated with circadian disruption [35].
6.2. Low Levels of Endogenous Melatonin or Altered Expression of Its Receptors Are Associated with Increased
Cancer Risk
Many groups, including ours, showed that high levels of endogenous melatonin measured
many years before the onset of breast cancer were associated with a reduction of breast cancer
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occurrence [15,16]. Other sets of evidence suggested a protective role of circulating melatonin on
prostate cancer development [17].
Conversely, two recent translational studies showed a lower expression of MT1 and MT2 receptors
in colon cancer tissues compared to matched normal tissues, suggesting melatonin’s protective role in
colon cancer development [159,160]. A negative correlation between melatonin receptor expression
and cancer has also been observed in Oral Squamous Cell Carcinoma (OSCC), where a reduced
expression of MT1 is also related to the T stage of tumor [186], and in breast cancer, where a lower
MT1 expression is associated with a poorer prognosis [156], together with a higher tumor grade and
TNM staging [187]. Finally, in Renal Cell Carcinoma (RCC) MT1 receptor expression was found to be
lower in cancer tissue compared to normal tissue [104].
7. A Possible Crosstalk between Melatonin Signaling and the Hippo Tumor Suppressor Pathway
As mentioned above, melatonin signals in part through MT1 and MT2 GPCR receptors. Recently,
GPCR signaling has been shown to regulate the Hippo pathway, which controls animal organ
development and growth and whose dysregulation is often involved in tumorigenesis (reviewed
in [188]). Components of the Hippo pathway include membrane-associated proteins that sense cell
polarity, cell density, and mechanical and metabolic cues that in turn activate a cascade of kinases with
adaptor proteins whose final targets are the transcriptional coactivators YAP and TAZ. YAP/TAZ work
as oncogenes in many solid cancers, where they are often upregulated or hyperactivated compared to
normal tissues (reviewed in [188]).
When the Hippo cascade is on, phosphorylation of YAP and TAZ by LATS1/2 kinases results in
their nuclear export, cytoplasmic retention [189–194], and degradation by the proteasome [195–197].
When the Hippo cascade is off, YAP/TAZ are dephosphorylated and are able to exert their nuclear
function and promote transcription of oncogenes in association with oncogenic transcription factors
such as TEADs, SMADs, and others [188].
Since YAP/TAZ are becoming increasingly attractive and promising therapeutic targets in cancer
treatment (reviewed in [198]), much importance is being placed on the discovery and characterization
of inhibitors of YAP/TAZ oncogenic function. What is melatonin’s role in this scenario? At present,
no literature has been produced on this topic. However, numerous independent sets of evidence
suggest a potential antagonism between melatonin signaling and YAP/TAZ oncogenic function;
we will try to summarize them in the following sections.
7.1. Gαs May Be a Common Molecular Intermediate between Melatonin Signaling and
GPCR/YAP/TAZ Signalng
GPCR signaling regulates YAP/TAZ in response to several biochemical stimuli and YAP/TAZ
can be either activated or inhibited depending on which GPCR and subsequent Gα protein is activated.
For example, LPA, S1P, and thrombin activate Gαi, Gαq, and Gα12/13, which, in turn, activate
YAP/TAZ by inducing their dephosphorylation mediated by Protein Phosphatase 1A (PP1A) and
by repressing LATS1/2 kinase activity. This mechanism requires the Rho GTPase RhoA and its
associated kinase ROCK and results in YAP/TAZ nuclear translocation [199–203]. In contrast, glucagon,
epinephrine, and dobutamine, which transmit signal from Gαs, inhibit YAP/TAZ. One of the proposed
mechanisms mediated by Gαs is an increased intracellular cAMP that leads to the activation of
protein kinase A (PKA). This in turn inhibits the RhoA/ROCK signaling and stimulates LATS1/2 to
phosphorylate YAP/TAZ, which are sequestered in the cytoplasm [203–205]. The inhibitory effect
of cAMP accumulation on oncogenic YAP/TAZ is conserved in different cell lines, including breast
metastatic MDA–MB-231, U2OS, MCF10A, HEK293A, and mouse embryonic fibroblasts (MEFs) [205].
Similarly, melatonin has been shown to activate Gαs proteins associated with MT1 receptors
in prostate cell lines [53–55,65–67], Cos-7 cells [68], and HEK293 cells [69], as well as to increase
intracellular cAMP with subsequent activation of PKA and PKC. Thus, the activation of PKA and
PKC mediated by Gαs in response to different stimuli (glucagon, epinephrine, dobutamine, melatonin)
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may lead to inhibition of cell proliferation and invasiveness through multiple converging mechanisms,
including LATS1/2 activation [203–205] and, as mentioned above, inhibition of NF-κB transcriptional
activity and inhibition of the AR response in AR positive cells [55]. Moreover, a recent study showed
that TAZ promoter is directly targeted and activated by NF-κB [206] suggesting that melatonin may
potentially inhibit YAP/TAZ pro-oncogenic function either through increasing LATS1/2 activity
(following PKA and PKC activation) or reducing TAZ transcription (following NF-κB inhibition)
(Figure 2).
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Figure 2. Interplay between G-Protein Coupled Receptors (GPCR) signaling regulated by melatonin
and GPCR signaling regulating YAP/TAZ. MT1 binding by melatonin (MLT) induces activation of
associated Gαq and Gαs that leads to the accumulation of intracellular cAMP that in turn activates
Protein Kinase A (PKA) and PKC. These in turn inhibit NF-κB transcriptional activity on its target
promoters, including TAZ promoter. In Androgen Receptor (AR) positive cells, PKA and PKC inhibit
the androgen response on AR responsive genes. In parallel, glucagon, epinephrine, and dobutamine
signal through Gαs, inducing increased intracellular cAMP and activation of PKA. This in turn inhibits
the RhoGTPase RhoA and activates LATS1/2 kinases, resulting in phosphorylation of YAP/TAZ, their
cytoplasmic sequestration by 14-3-3 protein, their degradation mediated by βTrCP, and the impairment
of their nuclear activity o pro-proliferative, pro-metastatic, a d nti- poptotic genes. ↑ indicates an
incre se in protein levels or activity; ↓ indicates a decrease in protein levels or activity.
7.2. Metabolic Pathways: Antagonism between Melatonin and YAP/TAZ
Beyond GPCR signali g, YAP/TAZ are also regulated by cell-cell contact, mechanical forces, and
metabolic cues. These induce specific intracellular signaling affecting YAP/TAZ function thr ugh
Hippo kinase cascade-dependent and independent mechanisms. Before going into m re detail, some of
these mechanisms may crosstalk with melatonin signaling. In general, we hypothesize an antagonism
between melatonin and YAP/TAZ on multiple mechanisms involved in tumorigenesis.
Insulin, insulin-like growth factors (IGF-I), nutrient intake, and other growth factors upregulate
cellular biosynthetic pathways to sustain cellular growth and proliferation through the activation of
protein kinases AKT/PI3K and mammalian target of rapamycin (mTOR) [207–211]. It has recently
been shown that insulin and GPCR signaling engage in crosstalk and synergize to positively regulate
YAP nuclear function onto YAP/TEAD target genes in pancreatic ductal adenocarcinoma (PDAC)
cells via PI3K activation [212]. YAP has been shown in turn to positively regulate the insulin and
the IGF-1 signaling [213] to drive IGF-2 expression, activ te mTOR signaling and AKT [214–216],
promote glucose uptake and glycolysis [217], driving growth advantage, metastatic compe ence,
Int. J. Mol. Sci. 2017, 18, 1913 8 of 26
angiogenesis, and therapy resistance in various model systems. On the other hand, melatonin
was shown to inhibit AKT/mTOR signaling in models of ovarian cancer [104], breast cancer [218],
hepatoma [219], and melanoma [220], where AKT/mTOR are aberrantly hyperactivated and contribute
to carcinogenesis [221]. Moreover, melatonin decreases insulin production from pancreatic β cells
while increasing the expression and secretion of glucagon from pancreatic α cells [222]. Since glucagon
is a negative regulator of YAP/TAZ nuclear function, as mentioned above, melatonin may indirectly
inhibit nuclear YAP/TAZ through glucagon upregulation.
Interestingly, AKT and the Insulin Receptor Scaffold 4 (IRS4) have been shown to co-purify with
MT2 receptor by Daulat and co-workers [223–225].
Together, this body of evidence suggests potential cross-talk between melatonin signaling, Hippo
signaling, and insulin–glucagone signaling, in agreement with a growing literature that showing a
reciprocal regulation between YAP/TAZ and metabolism on the one hand [226] and between melatonin
and metabolism on the other [227,228] (Figure 3).
Int. J. Mol. Sci. 2017, 18, 1913  8 of 25 
 
competence, angiogenesis, and therapy resistance in various model syst ms. On the other hand, 
mel tonin was shown to inhibit AKT/mTOR signaling in models of ovarian ancer [104], breast 
cancer [218], hepatoma [219], and elanoma [220], where AKT/mTOR are aberrantly hyperactivated 
and contribute to carcinogenesis [221]. Moreover, melatonin decreases insulin production from 
pancreatic β cells while increasing the expression and secretion of glucagon from pancreatic α cells 
[222]. Since glucagon is a negative regulator of YAP/TAZ nuclear function, as mentioned above, 
melatonin may indirectly inhibit nuclear YAP/TAZ through glucagon upregulation. 
Interestingly, AKT and the Insulin Receptor Scaffold 4 (IRS4) have been shown to co-purify 
with MT2 receptor by Daulat and co-workers [223–225]. 
Together, this body of evidence suggests potential cross-talk between melatonin signaling, 
Hippo signaling, and insuli –glucagone sign ling, in agreement with a growing literature that 
showin  a reciprocal r gulation between YAP/TAZ and metabolism on the one hand [226] and 
between melatonin and metabolism on the other [227,228] (Figure 3). 
 
Figure 3. Interplay between melatonin, YAP/TAZ, and metabolic pathways. Melatonin (MLT) 
upregulates glucagon production and downregulates insulin production and signaling. Glucagon 
inhibits YAP/TAZ nuclear function through Gαs signaling. Conversely, insulin and GPCR signaling 
synergize to positively regulate nuclear YAP onto YAP/TEAD target genes. In addition, YAP/TAZ 
activate AKT and mTOR, which are part of the insulin signaling. In conclusion, melatonin may 
inhibit YAP/TAZ nuclear function by inducing glucagon expression and decreasing insulin 
expression. On the other hand, YAP/TAZ positively regulate insulin signaling, and, vice versa, 
insulin signaling positively regulates YAP, suggesting an antagonism between melatonin function 
and nuclear YAP/TAZ function. Arrows indicate activation, while dashed and blunt lines indicate 
inhibition. The figure also shows the interaction between the insulin receptor scaffold 4 (IRS4) with 
insulin receptor, integrins, and MT1/2 receptors potentially linking these transmembrane proteins at 
the cell membrane. IR = Insulin Receptor, IRS1/2/4 = insulin receptor scaffold 1/2/4. 
7.3. Mechanotransduction and Chemoresistance: Opposite Roles of Melatonin and YAP/TAZ 
Mechanotransduction is a process where mechanical forces coming from the extracellular 
matrix (ECM) and from the cytoskeleton are transduced into cellular biochemical signals to regulate 
cell growth and survival. YAP/TAZ are widely recognized mechanotransducers and 
mechanoeffectors. They are preferentially active in the nucleus when cells are grown at low density, 
or on a stiff extracellular substrate, conditions where the cell–ECM contact area is larger and the 
Figure 3. Interplay between melatonin, YAP/TAZ, and metabolic pathways. Melatonin (MLT)
upregulates glucagon production and downregulates insulin production and signaling. Glucagon
inhibits YAP/TAZ nuclear function through Gαs signaling. Conversely, insulin and GPCR signaling
synergize to positively regulate nuclear YAP onto YAP/TEAD target genes. In addition, YAP/TAZ
activate AKT and mTOR, which are part of the insulin signaling. In conclusion, melato in may i hibit
YAP/TAZ nuclear functi n by inducing glucagon expression and decreasing insulin expression. On the
other hand, YAP/TAZ positively regulate insulin signaling, d, vice versa, insulin sig aling positively
regulates YAP, suggesting an antagonism between melatonin function and nuclear YAP/TAZ function.
Arrows indicate activation, while dashed and blunt lines indicate inhibition. The figure also shows the
interaction between the insulin receptor scaffold 4 (IRS4) with insulin receptor, integrins, and MT1/2
receptors potentially linking these transmembrane proteins at the cell membrane. IR = Insulin Receptor,
IRS1/2/4 = insulin receptor scaffold 1/2/4.
7.3. Mechanotra sduction and Chemoresistance: Opposite Roles of Melatonin and YAP/TAZ
Mechanotransduction is a process where mechanical forces coming from the extracellular
matrix (ECM) and from the cytoskeleton are transduced into cellular biochemical signals to
regulate cell growth and survival. YAP/TAZ are widely recognized mechanotransducers and
mechanoeffectors. They are preferentially active in the nucleus when cells are grown at low
density, or on a stiff extracellular substrate, conditions where the cell–ECM contact area is larger
and the cytoskeleton is subjected to a stronger mechanical stimulation (often the case of a tumor
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microenvironment). Conversely, YAP/TAZ effectors translocate to the cytoplasm in response to
high cellular density/cell contact, or on a soft extracellular substrate, where the cell experiences
lower mechanical stress [189,229–237]. Once activated, YAP/TAZ are able to regulate genes involved
in extracellular matrix remodelling [238,239]. Matrix rigidity plays an important role in tumor
development because it changes during tumorigenesis and regulates cell proliferation, stemness, and
invasiveness, and also the response of cancer cells to various chemotherapy agents, through different
pathways including YAP and TAZ regulation among others [240–243]. Accordingly, a role for YAP/TAZ
in increasing the resistance of cancer cells to various chemotherapy agents has been extensively
documented [243–248]. Conversely, melatonin treatment has been shown to partially overcome
resistance to chemotherapy, suggesting a possible antagonism between melatonin and YAP/TAZ in
cancer chemoresistance [24,102,103,130–134]. In response to mechanical stress, the stabilization of
cytoskeletal F-actin fibers and the activation of RhoA–ROCK facilitate YAP/TAZ nuclear translocation,
while F-actin destabilization induces YAP/TAZ phosphorylation and cytoplasmic retention. Currently,
the gap between YAP/TAZ and these upstream transducers remains to be filled and it would be
interesting to see what role melatonin signaling may play in this process. Some bodies of evidence
suggest melatonin’s role in mechanotransduction: melatonin has been shown to regulate cytoskeletal
dynamics in vitro [249–251] and in vivo [252,253], and to reduce the expression of the RhoA kinase
ROCK [124,126,127]. Moreover, Daulat and coworkers characterized several proteins interacting with
MT1 and MT2, among which is Filamin A [223–225], an actin-binding protein that contributes to the
cross-linking of cortical actin filaments into a dynamic three-dimensional structure and is involved in
mechanotransdution [254].
Akbarzadeh and co-workers’ recent work showed that ovarian cancer cells responded differently
to melatonin treatment (in terms of cell proliferation, morphological changes, and stemness) depending
on the composition of the extracellular matrix where they were cultured [145]. In this work, the authors
showed for the first time the role played by mechanical cues in regulating the response of cells
to melatonin.
7.4. Cell Contact/Polarity and RhoA/ROCK Signaling
Epithelial tissues line the surface of the animal body and internal cavities. They are composed
of cells oriented in the space with an apical-basal polarity. Several proteins contribute to the proper
cell-cell adhesion, orientation and spatial organization within the tissue and their dysregulation can
promote tumor development and metastasization [255–257]. In general, proteins involved in cell
contact/junction and cell polarity negatively regulate YAP/TAZ nuclear function by sequestering
YAP/TAZ at the apical plasma membrane, thus excluding them from the nucleus, and by interacting
with and activating Hippo pathway core kinases [195,255,258–272]. Catenin δ1 (p120 catenin),
a scaffold protein linking cytoskeletal actin fibers to adherens junctions at the plasma membrane,
has been co-purified with MT1 and MT2 by Daulat and co-workers [223–225]. p120 has been
shown to inhibit nuclear YAP and TAZ when localized at cellular junctions through inhibition of
RhoA–ROCK signaling [273–276], as well as to stabilize cell adhesion cadherin complexes [277–279]
that negatively regulate YAP/TAZ nuclear function [270,280]. Melatonin by itself reduces the migration
and invasiveness of different cancer types by increasing the expression of E-cadherin and other
adhesion molecules [122–125] and by reducing the expression of the RhoA kinase ROCK [124,126,127].
Rac1, a Rho GTPase that can functionally counteract RhoA [281,282], and the Ras-related GTPase
Rap1 that activates Rac1 [283], have been co-purified with MT1 [223]. Together, this body of evidence
suggests a possible role of melatonin and proteins associated with their receptors in the inhibition of
the YAP/TAZ pro-oncogenic and metastatic function, through the inhibition of RhoA-ROCK signaling
and via the stabilization of cell surface adhesion proteins [256].
Moreover, the MT1 receptor has been shown to interact with PDZ domain proteins including
MUPP1 and the neuronal NO synthase (NOS) [225,284,285], while MT2 has been co-purified with
14-3-3 protein [223]. MUPP1 is concentrated at tight junctions at the apical membrane and, together
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with ZO-1 and other scaffold proteins, anchors the integral proteins of tight junctions to the F-actin
cytoskeleton and contributes to their correct function and localization [286]. TAZ, containing a
PDZ-binding motif, has been shown to interact both with ZO-1 and 14-3-3, which tether TAZ at the
plasma membrane, thus inhibiting its nuclear function [189,192,193,268]. Also Gαi2, Gαo, and Gα12
have been shown to interact with ZO-1 in different systems and regulate tight junction assembly and
permeability [287,288], while MUPP1 has been shown to promote Gαi coupling and signaling of the
MT1 receptor [268,285]. Recently, YAP has been found in complex with the nitric oxide synthase 1
adaptor protein (NOS1AP) at cell-cell contacts together with the Scribble polarity complex [289,290],
a negative regulator of YAP/TAZ pro-oncogenic function [245,291]. This interaction increases YAP
phosphorylation and cytoplasmic sequestration. Interestingly, MT1 has been co-purified with the
nitric oxide synthase (NOS). All these sets of evidence suggest a structural and functional role of cell
polarity and cell contact proteins in the regulation of both the Hippo pathway and GPCR/MT1/MT2
signaling, which may converge in the inhibition of YAP/TAZ nuclear function. All these interactions
are schematically represented in Figure 4.
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Figure 4. Interplay between melatonin signaling, cell contact-cell polarity complexes, mechanotransduction,
and YAP/TAZ. Melatonin signaling inhibits RhoA/ROCK and increases the expression of cell surface
adhesion molecules such as E-cadherin. This suggests that it may inhibit YAP/TAZ nuclear function,
which in turn is promoted by RhoA/ROCK and inhibited by cell adhesion molecules. P120 catenin
has been co-purified with MT1/MT2 receptors. When localized at the plasma membrane, it stabilizes
E-cadherin at the adherens junction (AJ) while inhibiting RhoA–ROCK, thus inhibiting nuclear
YAP/TAZ (Y/T). MT1/2 also co-purified with MUPP1 scaffold protein, which interacts with ZO-1 at
tight junctions (TJ). Moreover, several studies showed that ZO-1 binds Gα proteins. This suggests a
possible interaction with TAZ, which has been demonstrated to be sequestered at the plasma membrane
through its interaction with ZO-1 at tight junctions. Moreover, YAP/TAZ may be seque tered at the
plasma membrane by the 14-3-3 protein, which has b en co-purified with MT1 and MT2. MT1/2
have also been co-purified with filaminA, involved in mechanotransdution, suggesting a link between
melatonin receptor signaling and mechanotransduction, which has been demonstrated to regulate
YAP/TAZ function and to be in turn controlled by YAP/TAZ. Finally, YAP has been co-purified with
NOS1AP (nitric oxide synthase1 adaptor protein) in the complex formed with the scribble polarity
proteins in proximity to cell–cell contacts. As NOS (nitric oxid syntase) has been co-purified with
MT1/MT2, this again may suggest a possible indirect interaction of YAP with MT1/MT2 at the plasma
membrane. In general, YAP/TAZ sequestration at the plasma membrane prevents their nuclear
pro-proliferative function. Arrows indicate activation, while dashed and blunt lines indicate inhibition.
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7.5. Opposite Roles of YAP/TAZ and Melatonin in Androgen–Estrogen Receptor Response and Angiogenesis
Melatonin inhibits the proliferation of Estrogen Receptor α (ERα)-positive lines more efficiently
than ERα-negative lines, suggesting that part of its antiproliferative effect is mediated by the inhibition
of the estrogen response. In fact, melatonin is able to inhibit the synthesis of steroids as well as interfere
with the binding of the ER to its target genes [128,150–153]. Conversely, other studies showed that
melatonin signaling is modulated by antiestrogens in breast and ovarian cancer cells [292]. Similarly,
melatonin inhibits Androgen Receptor (AR) response in normal and malignant prostate epithelial
cells [147–149]. On the other hand, LATS1/2 kinases have been shown to attenuate the androgen
response in the prostate by inhibiting AR chromatin binding and transcriptional activity [293] as well as
promoting ER degradation and reduction of its transcriptional activity in the breast [294,295], suggesting
that melatonin signaling and Hippo signaling may converge to inhibit the ER and AR response.
Finally, melatonin inhibits angiogenesis by interfering with its Hif1α- and STAT3-mediated
transcription of VEGF [127,135–146]. Conversely, YAP stabilizes H1F1α in response to hypoxia [296],
suggesting an antagonistic role of melatonin and YAP/TAZ in angiogenesis regulation.
8. Conclusions
At present, promising preclinical and clinical studies suggest that melatonin may be a safe and
valid therapy for the treatment of several types of malignancies when administered concomitantly
with traditional therapies. In fact, melatonin has been shown to improve the response of patients to
different therapies while reducing their toxic effects. On the other hand, preclinical studies showed
that inhibitors of YAP/TAZ associated with traditional therapies reduce tumor growth as well as
radio- and chemoresistance in different types of cancers [198,215,243,245–248,297]. To our knowledge,
functional crosstalk between melatonin signaling and Hippo/YAP/TAZ signaling has never been
previously addressed in the literature. However, several experimental observations may suggest that
both the melatonin signaling and Hippo signaling pathways may intersect at different levels (GPCR
signaling, AKT/PI3K signaling, and mechanotransduction) and both may potentially inhibit the
oncogenic function of YAP and TAZ through many converging mechanisms. Although these potential
cross-talks need extensive experimental validation, they may open up a new field of investigation
with important implications for (1) a better understanding of melatonin- and YAP/TAZ-mediated
pathways, which are still not completely elucidated; and (2) the potential design of novel combinatorial
cancer treatments. Today, in fact, the use of pharmacological inhibitors of YAP/TAZ is still in the
preclinical phase, while melatonin is used in clinic in combination with other traditional therapies.
Studies in this new direction might be worth pursuing.
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